US drug price-control wheels in motion

2000 ◽  
Vol 279 (1) ◽  
pp. 11-11
Keyword(s):  
Drug Price ◽  
Price Control

scholarly journals The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals

2005 ◽  
Vol 20 (3) ◽  
pp. 185-196 ◽  
Author(s):  
Qingyue Meng ◽  
Gang Cheng ◽  
Lynn Silver ◽  
Xiaojie Sun ◽  
Clas Rehnberg ◽  
...  
Keyword(s):  
Drug Price ◽  
Control Policy ◽  
Price Control ◽  
Hospital Expenditures ◽  
The Impact

scholarly journals Does price regulation affect atorvastatin sales in India? An impact assessment through interrupted time series analysis

BMJ Open ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. e024200
Author(s):  
Sakthivel Selvaraj ◽  
Habib Hasan Farooqui ◽  
Aashna Mehta
Keyword(s):  
Time Series ◽  
Time Series Analysis ◽  
Market Share ◽  
Drug Price ◽  
Interrupted Time Series ◽  
Price Control ◽  
Price Regulation ◽  
Interrupted Time Series Analysis ◽  
Series Analysis ◽  
The Impact

ObjectiveThe objective of this study was to examine the impact of medicines price regulation (Drug Price Control Order, 2013) on the market share of atorvastatin in the Indian retail market for statins.SettingAll Indian states, January 2012 to December 2015.DesignQuasi-experimental—interrupted time series analysis.DataPharmaceutical sales audit data set from IMS Health (now IQVIA) for the 48-month period from January 2012 to December 2015.Outcome measureShare of atorvastatin (in percentage) in the Indian market for statins in terms of sales volumes.ResultsWe observed that the price regulation notification (Drug Price Control Orders, 2013) was associated with 0.12% (p<0.001; 95% CI 0.06 to 0.18) increase in the trend of the average monthly market share of atorvastatin (5 mg and 10 mg). After 31 months of price ceilings notification, the average market share of atorvastatin was 3.41% higher than would have been expected had the price ceilings not been notified. In sensitivity analysis, with a control, our findings remain robust, we observed a 0.16% (p<0.001; 95% CI 0.08 to 0.24) rise in the trend of average monthly market share of atorvastatin (5 mg and 10 mg) as compared with the change in the control.ConclusionsPrice control as a public intervention did improve the relative sales of atorvastatin in the statin market in India.

scholarly journals Drug price control order: the impact on pharmacoeconomics

2019 ◽  
Vol 8 (10) ◽  
pp. 2220
Author(s):  
Suchi M. Shah ◽  
Anil P. Singh ◽  
Parth K. Vachhani
Keyword(s):  
Drug Therapy ◽  
Drug Price ◽  
Price Control ◽  
Medical Specialties ◽  
Retail Prices ◽  
The Difference ◽  
Control Order ◽  
Microsoft Office ◽  
The Cost ◽  
The Impact

Background: The objective of the present study was to analyze the prices of metformin, losartan, atorvastatin, paracetamol and aspirin for the doses which are included in the list of Drug Price Control Order (DPCO) 2013.Methods: Current index medical specialties India, 37th year, April-July 2015 issue was used for analysis. The retail prices of the drugs in INR were tabulated in Microsoft Office Excel 2013. The prices of the above listed drugs were compared with prices of DPCO 2013 for the same doses of drugs. The analysis of drugs costing more than the prices listed in the DPCO with the margin of the difference in percentage was carried out.Results: Out of 25 brands of metformin 500 mg tablet, 11 (44%) brands had price higher than listed in DPCO 2013. Similarly, prices for losartan 25 mg and 50 mg tablets, 8 (25%) out of 32 and 11 (31.42%) out of 35 were higher respectively. For atorvastatin 5 mg and 10 mg tablets, 2 (9.52%) out of 21 and 8 (13.55%) out of 59 brands had higher prices. For paracetamol 500 mg tablet, 12 (63.15%) out of 19 brands were priced higher than DPCO list. For aspirin 100 mg tablet and 325 mg tablet, 3 (100%) out of 3 brands and 1 (100%) out of 1 brand had higher prices.Conclusions: Many of the brand formulations have higher prices than the DPCO 2013 issued by government of India. The clinicians prescribing these drugs should be aware of these brand formulations to reduce the cost of the drug therapy.

Drug price control in Malaysia: a stakeholder analysis

2021 ◽  
Vol ahead-of-print (ahead-of-print) ◽  
Author(s):  
Amirul Ashraf ◽  
Siew Chin Ong
Keyword(s):  
Public Sector ◽  
Drug Price ◽  
Strong Support ◽  
Price Control ◽  
Pharmaceutical Pricing ◽  
Political Will ◽  
Content Type ◽  
The Public ◽  
The Government ◽  
High Chance

PurposePharmaceutical pricing has always been a contentious issue around the world. Recently, the Government of Malaysia has proposed for drug price control. This proposal has received backlash from pharmaceutical industry. Therefore in this study, the authors would like to examine the position of various stakeholders on this issue.Design/methodology/approachThe authors used Policy Maker software to identify and evaluate the position of the stakeholders, their interest and their power. Next, the authors contextualize the factors that might contribute to the success or failure of the policy using Kingdon's multiple stream analysis.FindingsThe authors found that the drug price control regulation received mixed reactions from the stakeholders, with the public sector mainly supporting the proposal whereas the private sectors opposing it. The findings indicate that the drug price control proposal have a high chance of success due to strong political will from both the government and the opposition and also strong support from the public and the consumer groups.Practical implications1. The drug price control proposal received strong political will and strong public support. Thus, it has a high chance of success. 2. The government should be careful in managing concentrated powerful groups. The government should strategically engage with the stakeholders to move them to more positive attitude. 3. The government should avoid backtracking on policies as this will portray critical weakness to other stakeholders.Social implicationsThe public sector provides strong support for the regulation. However, this support must be maintained and remain as their top priority. Their opinions are important in shaping health policies. The public's feedback will provide transparency and accountability in the policy-making process.Originality/valueThe findings indicate that the drug price control proposal have a high chance of success due to strong political will from both the government and the opposition and also strong support from the public and the consumer groups.

scholarly journals Cost comparison of commonly used antidepressant drugs with drug price control order in India

2019 ◽  
Vol 9 (1) ◽  
pp. 186
Author(s):  
Narendra Kumar ◽  
Alisha Abbas ◽  
Akhlaque Ahmad ◽  
Reshma Choudhary ◽  
Arpan Ganguly ◽  
...  
Keyword(s):  
Drug Price ◽  
Antidepressant Drugs ◽  
Price Control ◽  
Cost Comparison ◽  
Pharmaceutical Companies ◽  
Indian Market ◽  
Pharmaceutical Pricing ◽  
Ceiling Price ◽  
Strict Regulation ◽  
Control Order

Background: Price of a drug is an important factor for compliance to the treatment. So, to overcome the high prices of drugs, National Pharmaceutical Pricing Authority (NPPA) under government of India has issued Drug Price Control Order (DPCO) list containing commonly used drugs. Pharmaceutical companies can be punished if they keep their prices higher than the ceiling price mentioned in the DPCO. To find out the price variations of commonly used antidepressant drugs included in DPCO list of 29th April 2019.Methods: A list of all oral antidepressant drugs included in DPCO of 29th April 2019 and available in Indian market was procured from medguide India. Analysis of number of total brands following as well as not following DPCO ceiling price was done.Results: Author found 17 formulations of four antidepressant drugs included in DPCO. Total 556 brands found out of which 84.6% were following the DPCO and 15.4% of brands prices were higher than the ceiling price of DPCO.Conclusions: Though large number of companies are following the DPCO but still strict regulation is needed to further increase the compliance of guidelines.

Sign in / Sign up

Export Citation Format

Share Document